<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72305">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164422</url>
  </required_header>
  <id_info>
    <org_study_id>1308012557</org_study_id>
    <secondary_id>R01AA022285</secondary_id>
    <nct_id>NCT02164422</nct_id>
  </id_info>
  <brief_title>Does Guanfacine Attenuate Stress-Induced Drinking?</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating the effect of guanfacine on alcohol consumption. The investigators hypothesize
      that guanfacine versus placebo will decrease the number of drinks consumed during the 2-hour
      self-administration period across stress and neutral/relaxing conditions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of drinks consumed</measure>
    <time_frame>2 hour self administration period during lab sessions held on days 22 and 25</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alcohol craving</measure>
    <time_frame>2-hour self administration period during lab sessions held on days 22 and 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of drinks per week</measure>
    <time_frame>3 week titration prior to lab sessions, days 1-21</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Days 1-25, titration phase and lab sessions</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Alcohol Drinking</condition>
  <arm_group>
    <arm_group_label>Guanfacine 3mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Guanfacine 3mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Guanfacine 1.5mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Guanfacine 1.5mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanfacine 3mg/day</intervention_name>
    <description>3 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.</description>
    <arm_group_label>Guanfacine 3mg/day</arm_group_label>
    <other_name>Tenex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanfacine 1.5mg/day</intervention_name>
    <description>1.5 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.</description>
    <arm_group_label>Guanfacine 1.5mg/day</arm_group_label>
    <other_name>Tenex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21-65

          -  Able to read and write English

          -  Meets Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for
             current (past 6 months) alcohol abuse or alcohol dependence

        Exclusion Criteria:

          -  Participants with any significant current medical conditions, seizures, delirium or
             hallucinations, or other unstable medical conditions including HIV

          -  Current DSM-IV abuse or dependence on substances, other than alcohol abuse, alcohol
             dependence, or nicotine dependence

          -  Women who are pregnant or nursing

          -  Suicidal, homicidal or evidence of current (past 6-month) mental illness

          -  Meet DSM-IV criteria for current (past-6 month) attention deficit hyperactivity
             disorder (ADHD)

          -  Specific exclusions for administration of guanfacine not already specified include:
             EKG evidence at baseline screening of any clinically significant conduction
             abnormalities or arrhythmias; known intolerance for guanfacine or any alpha blocker;
             history of fainting, syncopal attacks, heart failure or myocardial infarction, or
             impaired liver as indicated by aspartate aminotransferase (AST), alanine
             aminotransferase (ALT) &gt; 3x normal or renal function (estimated creatinine clearance
             &lt;60 cc/min); treatment with any antihypertensive drug or any alpha-adrenergic
             blocker; use of any central nervous system (CNS) depressant (e.g., phenothiazines,
             barbiturates, benzodiazepines)

          -  Subjects likely to exhibit clinically significant alcohol withdrawal during the
             study.

          -  Individuals who are seeking treatment for drinking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherry A McKee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paula Cunningham</last_name>
    <phone>203-737-3554</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meaghan Lavery</last_name>
    <phone>203-737-2783</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale Center for Clinical Investigations, Yale University</name>
      <address>
        <city>New Haven,</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Cunningham</last_name>
      <phone>203-737-3554</phone>
    </contact>
    <investigator>
      <last_name>Sherry A McKee, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 22, 2016</lastchanged_date>
  <firstreceived_date>May 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Sherry McKee</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Alcohol</keyword>
  <keyword>Drinkers</keyword>
  <keyword>Guanfacine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Guanfacine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
